Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Cancer Discov. 2021 Feb 25;11(7):1688–1699. doi: 10.1158/2159-8290.CD-20-1598

Figure 2.

Figure 2.

Mean plasma concentrations of mobocertinib A. following the first oral administration of mobocertinib on Cycle 1, Day 1 and B. following repeated oral dosing on Cycle 2, Day 1 in patients with NSCLC in the dose-escalation study (semi-log scale).

Abbreviations: NSCLC, non–small cell lung cancer.

Preliminary pharmacokinetic data as January 27, 2020.